Short stature and language development in the United Kingdom: a longitudinal analysis of children from the Millennium Cohort Study.

Child development Cognition Cognitive development Height Linear growth Short stature Stunting

Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
05 12 2022
Historique:
received: 11 08 2022
accepted: 24 11 2022
entrez: 4 12 2022
pubmed: 5 12 2022
medline: 7 12 2022
Statut: epublish

Résumé

In low- and middle-income countries, poverty and impaired growth prevent children from meeting their cognitive developmental potential. There are few studies investigating these relationships in high-income settings. Participants were 12,536 children born between 2000 and 2002 in the UK and participating in the Millennium Cohort Study (MCS). Short stature was defined as having a height-for-age 2 or more standard deviations below the median (≤ - 2 SDS) at age 3 years. Standardized British Abilities Scales II (BAS II) language measures, used to assess language development at ages 3, 5, 7 and 11 years, were the main outcome assessed. Children with short stature at age 3 years (4.1%) had language development scores that were consistently lower from ages 3 to 11 years (- 0.26 standard deviations (SD) (95% CI - 0.37, - 0.15)). This effect was attenuated but remained significant after adjustment for covariates. Trajectory analysis produced four distinct patterns of language development scores (low-declining, low-improving, average and high). Multinomial logistic regression models showed that children with short stature had a higher risk of being in the low-declining group, relative to the average group (relative risk ratio (RRR) = 2.11 (95% CI 1.51, 2.95)). They were also less likely to be in the high-scoring group (RRR = 0.65 (0.52, 0.82)). Children with short stature at age 3 years who had 'caught up' by age 5 years (height-for-age ≥ 2 SDS) did not have significantly different scores from children with persistent short stature, but had a higher probability of being in the high-performing group than children without catch-up growth (RRR = 1.84 (1.11, 3.07)). Short stature at age 3 years was associated with lower language development scores at ages 3 to 11 years in UK children. These associations remained significant after adjustment for socioeconomic, child and parental factors.

Sections du résumé

BACKGROUND
In low- and middle-income countries, poverty and impaired growth prevent children from meeting their cognitive developmental potential. There are few studies investigating these relationships in high-income settings.
METHODS
Participants were 12,536 children born between 2000 and 2002 in the UK and participating in the Millennium Cohort Study (MCS). Short stature was defined as having a height-for-age 2 or more standard deviations below the median (≤ - 2 SDS) at age 3 years. Standardized British Abilities Scales II (BAS II) language measures, used to assess language development at ages 3, 5, 7 and 11 years, were the main outcome assessed.
RESULTS
Children with short stature at age 3 years (4.1%) had language development scores that were consistently lower from ages 3 to 11 years (- 0.26 standard deviations (SD) (95% CI - 0.37, - 0.15)). This effect was attenuated but remained significant after adjustment for covariates. Trajectory analysis produced four distinct patterns of language development scores (low-declining, low-improving, average and high). Multinomial logistic regression models showed that children with short stature had a higher risk of being in the low-declining group, relative to the average group (relative risk ratio (RRR) = 2.11 (95% CI 1.51, 2.95)). They were also less likely to be in the high-scoring group (RRR = 0.65 (0.52, 0.82)). Children with short stature at age 3 years who had 'caught up' by age 5 years (height-for-age ≥ 2 SDS) did not have significantly different scores from children with persistent short stature, but had a higher probability of being in the high-performing group than children without catch-up growth (RRR = 1.84 (1.11, 3.07)).
CONCLUSIONS
Short stature at age 3 years was associated with lower language development scores at ages 3 to 11 years in UK children. These associations remained significant after adjustment for socioeconomic, child and parental factors.

Identifiants

pubmed: 36464678
doi: 10.1186/s12916-022-02680-y
pii: 10.1186/s12916-022-02680-y
pmc: PMC9721056
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

468

Subventions

Organisme : Wellcome Trust
ID : 108065/Z/15/Z
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Int J Epidemiol. 2005 Jun;34(3):673-7
pubmed: 15746206
J Hum Resour. 2015 Spring;50(2):446-463
pubmed: 25983344
J Nutr. 2010 Nov;140(11):1996-2001
pubmed: 20844188
Am J Epidemiol. 1999 Apr 15;149(8):726-9
pubmed: 10206622
Lancet. 2002 Feb 16;359(9306):564-71
pubmed: 11867110
Horm Res Paediatr. 2016;85(5):325-32
pubmed: 27055026
J Nutr. 2010 Feb;140(2):348-54
pubmed: 20007336
Eur J Pediatr. 2011 Mar;170(3):351-8
pubmed: 20886355
Food Nutr Bull. 2006 Dec;27(4 Suppl Growth Standard):S212-23
pubmed: 17361658
Matern Child Nutr. 2020 Jan;16(1):e12864
pubmed: 31237738
Public Health Nutr. 2016 Jun;19(8):1339-47
pubmed: 26355426
PLoS Med. 2021 Sep 28;18(9):e1003760
pubmed: 34582440
J Pediatr. 2017 Mar;182:85-91.e3
pubmed: 28063689
J Pediatr. 2004 Apr;144(4):461-5
pubmed: 15069393
J Commun Disord. 2015 Sep-Oct;57:29-40
pubmed: 26028604
Pediatrics. 2015 May;135(5):e1266-75
pubmed: 25847806
Pediatrics. 2006 Sep;118(3):e682-9
pubmed: 16950960
Arch Pediatr Adolesc Med. 2004 Mar;158(3):236-43
pubmed: 14993082
J Pediatr. 1974 Oct;85(4):482-9
pubmed: 4443855
Am J Clin Nutr. 2013 Nov;98(5):1170-8
pubmed: 24004889
Lancet. 2005 Nov 19;366(9499):1804-7
pubmed: 16298218
J Nutr. 2021 Aug 7;151(8):2342-2352
pubmed: 33982126
J Paediatr Child Health. 2013 Mar;49(3):199-203
pubmed: 23432733
Int J Epidemiol. 2004 Dec;33(6):1320-8
pubmed: 15358746
PLoS One. 2017 Dec 13;12(12):e0189135
pubmed: 29236728
Psychol Bull. 2004 Nov;130(6):989-1013
pubmed: 15535745
Paediatr Perinat Epidemiol. 2012 Jul;26 Suppl 1:302-14
pubmed: 22742617
Int J Epidemiol. 2006 Jun;35(3):658-63
pubmed: 16446353
Behav Brain Funct. 2008 Jul 24;4:31
pubmed: 18652660
Soc Psychiatry Psychiatr Epidemiol. 2010 Nov;45(11):1023-35
pubmed: 19823757
Child Dev. 2021 Jan;92(1):115-123
pubmed: 32939765
Acta Paediatr. 2011 Aug;100(8):1113-8
pubmed: 21366692
SSM Popul Health. 2016 Dec;2:43-54
pubmed: 27110590
Arch Dis Child. 2002 Jan;86(1):11-4
pubmed: 11806873
Lancet. 2007 Jan 6;369(9555):60-70
pubmed: 17208643
Am J Trop Med Hyg. 2006 Mar;74(3):475-81
pubmed: 16525109
J Polit Econ. 2008;116(3):499-532
pubmed: 19603086
BMJ Glob Health. 2018 Jul 23;3(4):e000752
pubmed: 30058645
Paediatr Int Child Health. 2014 Nov;34(4):250-65
pubmed: 25310000
Arch Dis Child Fetal Neonatal Ed. 2005 Nov;90(6):F474-9
pubmed: 15956096
Infant Behav Dev. 2011 Feb;34(1):1-14
pubmed: 20970195
Arch Pediatr Adolesc Med. 2012 May;166(5):411-6
pubmed: 22566539
Child Dev. 1982 Oct;53(5):1157-63
pubmed: 7140424
Nutrition. 1992 Jul-Aug;8(4):285-97; discussion 298
pubmed: 1498462
J Nutr. 2018 Mar 1;148(3):311-315
pubmed: 29546307
Fertil Steril. 2015 Jun;103(6):1381-91
pubmed: 26041693
Am J Clin Nutr. 2013 Dec;98(6):1555-63
pubmed: 24067665
Lancet. 2008 Jan 26;371(9609):340-57
pubmed: 18206223
Am J Clin Nutr. 2014 Jul;100(1):182-8
pubmed: 24808488
Hum Reprod. 2017 Jul 1;32(7):1482-1488
pubmed: 28541549
BMJ. 1994 Mar 5;308(6929):641-2
pubmed: 8148716
Econ Hum Biol. 2021 May;41:100978
pubmed: 33610090
JAMA Pediatr. 2015 Dec;169(12):1162-72
pubmed: 26457641
Arch Public Health. 2016 May 02;74:17
pubmed: 27141306
Stat Methods Med Res. 2018 Jul;27(7):2015-2023
pubmed: 29846144
Demography. 2017 Apr;54(2):485-511
pubmed: 28233235
Nature. 2020 Jan;577(7789):231-234
pubmed: 31915393
Brain. 2004 Feb;127(Pt 2):321-9
pubmed: 14645144
BMJ. 2010 Mar 15;340:c1140
pubmed: 20231247
Dev Sci. 2013 Sep;16(5):676-87
pubmed: 24033573
J Nutr. 2018 Nov 1;148(11):1852-1859
pubmed: 30383284
Am J Clin Nutr. 2020 Jul 1;112(1):187-194
pubmed: 32239193
Pediatrics. 2014 Oct;134(4):e1001-8
pubmed: 25266433
Arch Dis Child. 2001 Mar;84(3):218-21
pubmed: 11207167
Am J Hum Biol. 2005 Jul-Aug;17(4):412-7
pubmed: 15981181
Early Hum Dev. 2018 May;120:53-60
pubmed: 29656171
Econ Hum Biol. 2011 Jul;9(3):272-6
pubmed: 21459057
Pediatrics. 1986 Oct;78(4):646-50
pubmed: 3763275
Arch Dis Child. 2016 May;101(5):422-6
pubmed: 26342096
Int J Epidemiol. 2002 Apr;31(2):342-8
pubmed: 11980795
Cochrane Database Syst Rev. 2015 Nov 24;(11):CD005495
pubmed: 26597166

Auteurs

Joseph Freer (J)

Queen Mary University of London, London, UK. j.freer@qmul.ac.uk.

Joanna Orr (J)

Queen Mary University of London, London, UK.

Joan K Morris (JK)

St George's, University of London, London, UK.

Robert Walton (R)

Queen Mary University of London, London, UK.

Leo Dunkel (L)

Queen Mary University of London, London, UK.

Helen L Storr (HL)

Queen Mary University of London, London, UK.

Andrew J Prendergast (AJ)

Queen Mary University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH